Application of Contemporary Neuroproteomic Techniques in Unravelling Neurological Disorders

被引:4
作者
Khurana, Mallika [1 ]
Rahman, Syed Obaidur [2 ]
Najmi, Abul Kalam [2 ]
Pottoo, Faheem Hyder [3 ]
Akhtar, Sayeed [4 ]
机构
[1] Univ Tsukuba, Sch Comprehens Human Sci, Tsukuba Life Sci Innovat, 1 Chome 1-1 Tennodai, Tsukuba, Ibaraki 3058577, Japan
[2] Jamia Hamdard, Sch Pharmaceut Educ & Res, Dept Pharmacol, Pharmaceut Med, New Delhi 110062, India
[3] Imam Abdulrahman Bin Faisal Univ, Coll Clin Pharm, Dept Pharmacol, POB 1982, Dammam 31441, Saudi Arabia
[4] King Khalid Univ, Coll Pharm, Dept Clin Pharm, Abha, Saudi Arabia
关键词
Neuroprotcomic Techniques; neurological Disorders; Alzheimer's disease; Parkinson's disease; multiple sclerosis; epilepsy; psychiatric disorders; Omics; MULTIPLE-SCLEROSIS PATIENTS; QUANTITATIVE PROTEOMIC ANALYSIS; ANTERIOR CINGULATE CORTEX; PLASMA APOLIPOPROTEIN A1; HUMAN SUBSTANTIA-NIGRA; CEREBROSPINAL-FLUID; ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; PSYCHIATRIC-DISORDERS; PROTEIN BIOMARKERS;
D O I
10.2174/1389203721666201104130135
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Decades of research has mimed us with the very distinctive anatomy and physiology of our brain, and on the other hand, its complexity has always posed great difficulty in treating its dysfunction or damage. Understanding the brain under normal and, particularly in the diseased state, has always been very challenging and would have been impossible without proteomics. Neuroproteomic techniques have been extensively used for unraveling both dynamics and content of the proteome of our nervous system. This modern-day investigation and quantification of protein concentration and expression have given us a platform that enhances our knowledge on disease-associated processes and pathways modification and also leads to the identification of possible biomarkers that can he therapeutically targeted. With an increased interest in identifying and targeting possible hiomarkers, this article focuses on describing applications of the much discussed neuroproteomics, with a significant role in the disease pathogenesis of some very common neurological disorders. This article will collectively discuss the use and relevance of neuroproteomics in a range of neurological diseases, such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, epilepsy, and psychiatric disorders. We have also attempted to present the current successes and failures of the neuroproteomics approach on the results obtained from different clinical studies that targeted hiomarkers associated with any particular neurological disorder.
引用
收藏
页码:1146 / 1163
页数:18
相关论文
共 172 条
  • [71] Proteomic identification of the involvement of the mitochondrial Rieske protein in epilepsy
    Junker, H
    Späte, K
    Suofu, Y
    Walther, R
    Schwarz, G
    Kammer, W
    Nordheim, A
    Walker, LC
    Runge, U
    Kessler, C
    Popa-Wagner, A
    [J]. EPILEPSIA, 2005, 46 (03) : 339 - 343
  • [72] Hypometabolism precedes limbic atrophy and spontaneous recurrent seizures in a rat model of TLE
    Jupp, Bianca
    Williams, John
    Binns, David
    Hicks, Rodney J.
    Cardamone, Lisa
    Jones, Nigel
    Rees, Sandra
    O'Brien, Terence J.
    [J]. EPILEPSIA, 2012, 53 (07) : 1233 - 1244
  • [73] Proteomic analysis of human epileptic neocortex predicts vascular and glial changes in epileptic regions
    Keren-Aviram, Gal
    Dachet, Fabien
    Bagla, Shruti
    Balan, Karina
    Loeb, Jeffrey A.
    Dratz, Edward A.
    [J]. PLOS ONE, 2018, 13 (04):
  • [74] Plasma protein biomarkers of Alzheimer's disease endophenotypes in asymptomatic older twins: early cognitive decline and regional brain volumes
    Kiddle, S. J.
    Steves, C. J.
    Mehta, M.
    Simmons, A.
    Xu, X.
    Newhouse, S.
    Sattlecker, M.
    Ashton, N. J.
    Bazenet, C.
    Killick, R.
    Adnan, J.
    Westman, E.
    Nelson, S.
    Soininen, H.
    Kloszewska, I.
    Mecocci, P.
    Tsolaki, M.
    Vellas, B.
    Curtis, C.
    Breen, G.
    Williams, S. C. R.
    Lovestone, S.
    Spector, T. D.
    Dobson, R. J. B.
    [J]. TRANSLATIONAL PSYCHIATRY, 2015, 5 : e584 - e584
  • [75] Decoding neuroproteomics: integrating the genome, translatome and functional anatomy
    Kitchen, Robert R.
    Rozowsky, Joel S.
    Gerstein, Mark B.
    Nairn, Angus C.
    [J]. NATURE NEUROSCIENCE, 2014, 17 (11) : 1491 - 1499
  • [76] Multiple reaction monitoring for quantitative biomarker analysis in proteomics and metabolomics
    Kitteringham, Neil R.
    Jenkins, Rosalind E.
    Lane, Catherine S.
    Elliott, Victoria L.
    Park, B. Kevin
    [J]. JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2009, 877 (13): : 1229 - 1239
  • [77] Krezel W, 1998, SCIENCE, V279, P863, DOI 10.1126/science.279.5352.863
  • [78] Cerebrospinal fluid proteome comparison between multiple sclerosis patients and controls
    Kroksveen, A. C.
    Guldbrandsen, A.
    Vedeler, C.
    Myhr, K. M.
    Opsahl, J. A.
    Berven, F. S.
    [J]. ACTA NEUROLOGICA SCANDINAVICA, 2012, 126 : 90 - 96
  • [79] Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis
    Kroksveen, Ann C.
    Jaffe, Jacob D.
    Aasebo, Elise
    Barsnes, Harald
    Bjorlykke, Yngvild
    Franciotta, Diego
    Keshishian, Hasmik
    Myhr, Kjell-Morten
    Opsahl, Jill A.
    van Pesch, Vincent
    Teunissen, Charlotte E.
    Torkildsen, Oivind
    Ulvik, Rune J.
    Vethe, Heidrun
    Carr, Steven A.
    Berven, Frode S.
    [J]. PROTEOMICS, 2015, 15 (19) : 3361 - 3369
  • [80] Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM
    Kroksveen, Ann C.
    Aasebo, Elise
    Vethe, Heidrun
    Van Pesch, Vincent
    Franciotta, Diego
    Teunissen, Charlotte E.
    Ulvik, Rune J.
    Vedeler, Christian
    Myhr, Kjell-Morten
    Barsnes, Harald
    Berven, Frode S.
    [J]. JOURNAL OF PROTEOMICS, 2013, 78 : 312 - 325